Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

An Army program for selecting unit commanders that a spokesman for defense chief Pete Hegseth condemned as "woke" selected White men for command roles at a higher rate than women and minority officers ...

The Army has cut a program it used in recent years to pick officers to lead battalions and brigades and select to the top enlisted leaders for those formations, the service’s Human Resources Command ...

The Army will review the use of selection boards to assess senior soldiers for command positions, officials said. In a memo Thursday, Secretary of the Army Dan Driscoll rescinded the official status ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

The original version of this story appeared in Quanta Magazine. Computer scientists often deal with abstract problems that are hard to comprehend, but an exciting new algorithm matters to anyone who ...

The latest chemistry news, including important research advances, business and policy trends, chemical safety practices, career guidance, and more. “Affinity was an open problem for decades,” Barzilay ...